title: Kanglaite injection combined with chemotherapy versus chemotherapy alone in the treatment of advanced non-small cell lung carcinoma.
abstract: OBJECTIVE
  To evaluate the clinical efficacy of Kanglaite (KLT) injection combined with chemotherapy versus chemotherapy alone in the treatment of advanced non-small cell lung carcinoma (NSCLC) by meta-analysis.
  
  
  METHODS
  Electronic search of PubMed, EMBASE, Chinese National Knowledge Infrastructure (CNKI) and Wanfang databases was conducted to select studies about KLT injection combined with chemotherapy versus chemotherapy alone in the treatment of advanced NSCLC. The pooled risk ratio (RR) and its 95% confidence interval (95% CI) for objective response rate (ORR), Karnofsky (KPS) score improvement and nausea and vomiting were calculated by Stata11.0 statistical software.
  
  
  RESULTS
  Finally, we included 34 clinical trials in this meta-analysis. The pooled results suggested that KLT injection combined with systematic chemotherapy can significantly increase the objective response rate (ORR) [RR = 1.35, 95% CI: 1.23-1.48, (Z = 6.43, P = 0.000)], the quality of patients' life (KSP improvement) [RR = 2.04, 95% CI: 1.79-2.33, (Z = 10.57, P = 0.000)] and decrease the risk ratio of gastrointestinal reaction [RR = 0.53, 95% CI: 0.42-0.66, (Z = 5.53, P = 0.000)] compared with chemotherapy alone.
  
  
  CONCLUSIONS
  KLT injection combined with chemotherapy can improve the short-term efficacy, performance status and decrease the risk of gastrointestinal reaction compared with systematic chemotherapy alone.
authors.forename: Xiaohong
authors.initials: X
authors.lastname: Liu
authors.forename: Qinghui
authors.initials: Q
authors.lastname: Yang
authors.forename: Yuling
authors.initials: Y
authors.lastname: Xi
authors.forename: Kewei
authors.initials: K
authors.lastname: Yu
authors.forename: Weizhen
authors.initials: W
authors.lastname: Wang
authors.forename: Xiangmei
authors.initials: X
authors.lastname: Zhao
authors.affiliation: Department of Oncology, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang 453100, China.
authors.forename: Xiaoge
authors.initials: X
authors.lastname: Kou
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000009:adverse effects; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000473:pathology; D004358:Drug Therapy; D004365:Drugs, Chinese Herbal / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D017567:Karnofsky Performance Status; D009367:Neoplasm Staging; D039781:PubMed
chemical_list: D000970:Antineoplastic Agents; D004365:Drugs, Chinese Herbal; C499781:kang-lai-te